This trial is designed to evaluate the antimycobacterial ejects and the safety of
alpibectir in combination with other antimycobacterial agents, particularly Eto, over a
14-day period. The overarching objective is to optimise the dose of both alpibectir and
ethionamide and to confirm the safety of the A45E250RZE regimen for future evaluation as
an alternative regimen for INH mono-resistant TB. The data from the TASK-010 phase 2A and
the ENABLE study will support evaluation of the optimal dose combination of AlpE to move
forward into later phase studies. EBAs have historically been conducted between 2 and 14
days. This study will be a standard 14-day EBA design with multiple parallel and
sequential treatment arms.
Cohort 1:
Arm 1 and 2: This cohort will add to the evidence base generated in the TASK-010 study
(NCT05473195) to support dose optimisation of alpibectir and ethionamide (AlpE) and
establish the safety of alpibectir 45 mg in humans, a dose which to date has not been
evaluated.
Interim safety review: once a safety review of a subset of participants in arms 1 and 2
receiving the 45 mg dose of alpibectir is complete, cohort 2 will be permitted to begin
recruiting once cohort 1 is complete.
Cohort 2:
Arm 4: will combine AlpE at doses determined to be safe and well tolerated from arms 1
and 2, with standard doses of rifampicin, isoniazid and ethambutol (A45E250RZE). Here
AlpE replaces isoniazid in the regimen as part of the planned future use of the
combination. This will establish the safety of this 5-drug combination at standard
rifampicin doses. A well tolerated, adorable, oral, once daily dosing regimen would make
the AlpE combination tolerable for patients and hence for the majority of people
suffering from TB in less affluent regions of the world. All participants will remain
under medical attention, and will be housed, and monitored in hospital from admission
through day 15 of the treatment period; this will allow for continuous monitoring of the
health status of each participant while initiating treatment, any of whom can be
withdrawn at any stage of the trial and removed from study treatment should his/her
condition suggest to the investigator that this would be in his/her best interest.
Biomarkers The traditional 2A proof-of-concept studies for new TB drugs also allow the
exploration of new ways of measuring TB treatment activity in short-course trials beyond
measurement of CFU or TTP. Each chemotherapeutic agent has the potential to contribute an
interactive, often synergistic, role with other agents in a combination regimen, but this
attribute is not captured by measuring decline in sputum CFU or TTP alone. Novel sputum
biomarkers, and biomarkers from blood samples may have the potential to substitute or
complement traditional sputum culture based methods to assess treatment responses. Host
derived markers may also be able to describe the EBA of novel drugs.
Whole blood biomarkers:
Whole blood RNA analysis is emerging as a promising tool for the pathogen-free diagnosis
and monitoring of TB treatment. This approach has the potential to revolutionize TB
management by oqering a precise, individualized method to determine the duration of
anti-TB therapy needed to achieve a relapse-free cure. The identification and validation
of a 22-gene transcriptomic signature model (TB22) by Heyckendorf and colleagues serve as
a significant advancement in this field. TB22 has shown superior performance in
predicting individual treatment endpoints compared to 17 other publicly available RNA
signatures. Specifically, TB22 demonstrated high accuracy in identifying end-of-therapy
time points, with an AUC of 0.94 for predicting clinical outcomes. The model also
indicated that cure could be achieved with significantly shorter treatment durations for
patients with multidrug-resistant TB (MDR-TB). Whole blood will be collected in
participants who consent for evaluation of whole blood RNA in models like the TB22 or
others investigating the use of novel biomarkers.
Sputum biomarkers:
The Molecular Bacterial Load Assay (TB-MBLA) and PATHFAST (LAM) are novel biomarkers
being evaluated for their potential to improve TB treatment monitoring. The TB-MBLA oqers
a rapid and precise measurement of bacterial load by detecting RNA, which is less aqected
by the presence of non-culturable bacteria. This assay, coupled with appropriate RNA
preservatives, can provide real-time insights into the bacterial burden and treatment
eqicacy. PATHFAST (LAM) focuses on detecting lipoarabinomannan (LAM) in sputum, a
component of the mycobacterial cell wall. LAM detection can serve as a biomarker for
active TB, providing an additional layer of diagnostic information. Its integration into
treatment monitoring can help assess the eqicacy of TB drugs, particularly in reducing
bacterial load in the lungs. These biomarkers will be evaluated for use as secondary and
exploratory endpoints in 2A setting within this protocol.
Study Drug Rationale Given the increasing need for novel regimens and highly eqective,
well-tolerated drugs to treat participants with TB, it is important to evaluate the
antituberculosis activity of established anti- TB drugs that have been enhanced to
generate higher eqicacy, lower adverse eqects, or both. These evaluations should occur in
a carefully conducted, controlled, and standardised EBA study to determine their
contributions as building blocks for potential future studies of new regimens. The
results of this study will be used to support future studies of longer duration. Activity
rationale: Extending the EBA duration from 7 to 14 days is informed by data suggesting
that the full antimycobacterial eqect of alpibectir may not be completely observable
within the 7-day period, thus a longer duration allows for a more accurate assessment of
its activity and safety. The absence of human data at this dose level warrants careful
monitoring, but the potential benefits of a more eqective treatment regimen for
INH-resistant and other DR-TB justify this exploration. Safety rationale: The inclusion
of a 45 mg dose of alpibectir in this study, despite not having been tested in previous
phase 1 or 2 trials, is expected to be safe and well tolerated. Appropriate safety
measures are in place to monitor participants throughout their treatment and evaluation
of this premise. Pharmacodynamic scaling from pre-clinical models to humans suggests that
the higher dose is likely to maximize therapeutic activity while maintaining a favourable
safety profile. Given the promising preclinical and phase 2A results, it is both
scientifically justified and ethically responsible to optimise the dose of alpibectir in
a controlled clinical trial. The trial design includes comprehensive safety assessments
to identify and manage any adverse events promptly. The investigation of 14 days in a
5-drug regimen (A45E250RZE) will provide crucial pilot safety and tolerability data.
Hepatotoxic eqects associated with RZE-based regimens may occur later in treatment, and
therefore 14-day data will provide some evidence on the safety of the regimen when moving
into later phases of development. This approach ensures that any potential hepatotoxic
eqects or other adverse events are identified and managed early, thereby safeguarding
participants and informing future phase studies.
Control rationale: HRZE is being used as the control arm as the current SOC for PTB.
Using HRZE allows for a direct comparison of the safety of the diqerent study arms
against WHO approved regimen, and a microbiological control.
Rationale for the Selection of the Agents and Doses Alpibectir Alpibectir increases
intra-bacterial bioactivation of Eto and as such works in combination with Eto to enhance
Eto exposure in TB without increasing the dose of Eto. The selection of a 45 mg dose of
alpibectir is based on pharmacodynamic scaling from animal models to humans, which
indicates that this dose is likely to maximize therapeutic activity while maintaining a
favourable safety profile, as evidenced by substantial bacterial load reduction in
preclinical trials. Preclinical data showing that alpibectir at doses of up to 1.6 mg/kg
prevented mortality in a BALB/c mouse model, suggesting a protective eqect of the drug at
higher doses. Combination therapy arms with alpibectir and Eto are grounded in the
compound's ability to enhance the bactericidal effect of Eto, as proven in pre-clinical
trials and the recent phase 2 EBA. The trial seeks to further evaluate the potential of
reducing the effective dose of Eto required, thus potentially reducing the drug's side
effects, and enhancing patient tolerability.
Regimens explored in the TASK-010 trial evaluating doses of 9 mg and 27 mg of alpibectir
along with Eto 120-500 mg, when pooled with the ENABLE 45 mg alpibectir and 125-250 mg
Eto will support PKPD modelling and establish a robust dose-response curve to support the
best dose combination.
Ethionamide Two doses of Eto will be used in this study, 125 mg, and 250 mg. EBA was seen
in both doses when combined with alpibectir 27 mg in the recent TASK-010 phase 2a trial,
these doses were also well tolerated in participants. The aim is to maintain a low,
active dose of Eto in combination with alpibectir to ensure tolerability.
Rifampicin (A45E250RZE) The inclusion of a combination arm with alpibectir, Eto and RZE
(Rifampicin, Pyrazinamide and Ethambutol) is designed to evaluate the EBA of the
combination as part of a comprehensive TB treatment regimen. This could potentially
inform the design of further trials. Additionally, we aim to assess whether the AlpE
combination can serve as a viable alternative INH, particularly in situations where INH
cannot be used due to resistance or other contraindications. This study will focus on the
safety of the A45E250RZE combination.
Pyridoxine All participants will receive pyridoxine as prophylaxis against
isoniazid-related or ethionamide related peripheral neuropathy, as per the National TB
Guidelines. Currently this is 25 mg orally once daily, or with each dose of isoniazid or
ethionamide.
ART Using the multi-cohort design, the early safety of the AlpE combination at higher
alpibectir doses will be determined, as well as the safety of the A45E250RZE combination.
In South Africa, between 1/3 and ½ patients diagnosed with TB are co-infected with HIV.
It is important to understand the impact ART will have on the activity of any TB drug or
regimen. As such, we have elected to include participants with HIV/TB co-infection who
are receiving one of a limited number of ART options currently recommended as first line
therapy. Inclusion of this critical group is unlikely to have significant impact either
on the activity of the regimens, or on the efficacy of the ART as determined by the known
effect of each drug on inhibiting or inducing various substrates involved in metabolism.
This allows the study to generate early safety data with minimal risk to the
participants. The ART regimens permitted include 2 non-nucleoside reverse transcriptase
inhibitors (NRTI) and dolutegravir. The NRTI's permitted may include Emtricitabine,
Lamivudine and/or Tenofovir.
Dolutegravir (Mondleki, 2022):
Dolutegravir does not induce or inhibit metabolising enzymes. Dolutegravir is a
substrate of the drug efflux pumps P-gp and BCRP. It is primarily metabolised by
enzyme UGT1A1, and to a smaller degree by CYP3A4, and UGT1A3 and 1A9.
Alpibectir has a minimal risk of inhibition of CYP3A4, P-gp, and BCRP (section 3.1).
No information is available about the effect of alpibectir on UGT1A1, although in
vitro work is planned and will be conducted. INH has a small effect on CYP3A4
inhibition, this effect may be more pronounced in slow acetylators though the
clinical effect is likely modest.
Based on the currently available data in which lower concentrations of dolutegravir
were found when co-administered with rifampicin but not impact on viral suppression
was demonstrated, a clinically significant drug-drug interaction between
dolutegravir and the AlpE combination or HRZE are not anticipated
(Sekaggya-Wiltshire, 2023). Current South African Department of Health guidelines
recommend increasing the dose of dolutegravir to 50 mg twice daily (from 50 mg
daily)(Primary Care Guide, 2021). This will be implemented in participants
randomized to arms receiving rifampicin.
Emtricitabine, Lamivudine, Tenofovir (NRTIs)
Emtricitabine, lamivudine and tenofovir are not substrates or inhibitors of CYP
enzymes but are substrates for various transporter proteins. For example, Tenofovir
is a substrate of BCRP/ABCG2 and P-glycoprotein/ABCB1, and an inhibitor of MRP2
(Wassner, 2020).
Based on the currently available data, a clinically significant drug-drug
interaction between the NRTIs and the AlpE combination or RZE are not anticipated.